Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile...
Read More Details
Finally We wish PressBee provided you with enough information of ( Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress )
Also on site :
- Kremlin comments on possible US strike on Iran
- Former NBA Player and 'Survivor' Alum Opens Up About Heart Transplant
- Syrian women’s sports suffer from lack of support and media attention